Arthur Moellman-Coelho

Suggest Changes
Learn More
Despite the relevant therapeutic progresses obtained with imatinib, clinical resistance to this drug has emerged and reemerged after cytogenetic remission in a group of patients with chronic myeloid(More)
  • 1